Skip to main content
Omega Therapeutics, Inc. (OMGA)
NASDAQ: OMGA · IEX Real-Time Price · USD
1.790
-0.050 (-2.72%)
At close: Jul 19, 2024, 4:30 PM
1.820
+0.030 (1.68%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

Omega Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
 TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Revenue
4.943.092.070.1400
Revenue Growth (YoY)
112.70%49.25%1339.58%---
Gross Profit
4.943.092.070.1400
Selling, General & Admin
27.6326.1923.6716.66.244.23
Research & Development
72.6277.1781.1747.8721.0611.93
Other Operating Expenses
-0.41001.711.371.17
Operating Expenses
99.83103.36104.8466.1828.6717.33
Operating Income
-94.89-100.26-102.77-66.03-28.67-17.33
Interest Expense / Income
0.68000.910.780.6
Other Expense / Income
-3.3-2.83-0.071.34-00.02
Pretax Income
-92.28-97.43-102.7-68.28-29.45-17.95
Net Income
-92.28-97.43-102.7-68.28-29.45-17.95
Shares Outstanding (Basic)
55544822413
Shares Outstanding (Diluted)
55544822413
Shares Change
8.93%12.80%113.71%473.56%-68.85%-
EPS (Basic)
-1.66-1.80-2.14-3.05-7.54-1.43
EPS (Diluted)
-1.66-1.80-2.14-3.05-7.54-1.43
Free Cash Flow
-77.96-93.73-99.9-59.08-27.94-16.56
Free Cash Flow Per Share
-1.41-1.74-2.09-2.64-7.15-1.32
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-1921.30%-3240.50%-4957.36%-45855.56%--
Profit Margin
-1868.35%-3148.93%-4954.22%-47416.67%--
Free Cash Flow Margin
-1578.42%-3029.38%-4818.86%-41025.00%--
EBITDA
-84.32-90.66-97.51-65.98-27.52-16.56
EBITDA Margin
-1707.15%-2930.09%-4703.86%-45821.53%--
Depreciation & Amortization
7.286.775.191.391.150.79
EBIT
-91.6-97.43-102.7-67.37-28.67-17.35
EBIT Margin
-1854.55%-3148.93%-4954.22%-46784.72%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).